Market Overview

Bernstein Weighs In On Vertex Move

Share:
Related VRTX
Vertex Pharmaceuticals' Phase 3 Studies Offer Ample Opportunity For Upside
Earnings Scheduled For July 27, 2016
Who's Next After Medivation? (Seeking Alpha)

As shares of Vertex Pharmaceuticals (NASDAQ: VRTX) have rallied over 40 percent following a press release concerning phase 3 studies of its Lumacaftor Ivacaftor combination regime, Bernstein analyst Geoffrey Porges issued a note with his take on the stock

Despite Tuesday's move, Porges maintained his Market Perform rating and $65 price target.

Porges noted the data are "clearly better than expected," but believes the immediate potential of the combination is substantially priced in. Moreover, he thinks short-covering will initially exaggerate the move.

Looking forward, Porges expects the regimen to receive FDA approval.

For a more detailed look into the press release, click here.

Latest Ratings for VRTX

DateFirmActionFromTo
Jul 2016Morgan StanleyMaintainsOverweight
Apr 2016Goldman SachsDowngradesBuyNeutral
Apr 2016Credit SuisseMaintainsOutperform

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Bernstein Geoffrey PorgesAnalyst Color News Price Target Reiteration Analyst Ratings

 

Related Articles (VRTX)

View Comments and Join the Discussion!